"Xing Fu Hu Xi", China COPD Tiered Diagnosis and Treatment Project 2019 Summary Meeting held in Beijing

On 20 November, "Xing Fu Hu Xi" (Happy Breath) China COPD Tiered Diagnosis and Treatment Project 2019 Summary Meeting was held in Beijing. The meeting summarised the achievements of "Xing Fu Hu Xi" project in the past two years and discussed the project plan for the next phase. With the support of GSK, the project has achieved significant progress in the implementation of COPD tiered treatment and diagnosis. Now, 50 whole-process COPD treatment and management medical consortia was established in 19 pilot cities and has benefited more than 7,500 patients with standardised COPD management. Moreover, hundreds of thousands healthcare professionals have received trainings on COPD diagnosis and treatment through activities including training programmes and online clinical case discussions.

Sponsored by the National Health Commission (NHC) and supported by GSK, "Xing Fu Hu Xi" project was launched in November 2017. The project is jointly organised by the Chinese Association for Health Promotion & Education and the Respiratory Subspecialty Cluster of China-Japan Friendship Hospital, co-organised by the Chinese Association of Chest Physicians. It was designed to promote the respiratory disease treatment and management medical consortia, and to better improve COPD tiered diagnosis and treatment across various levels of healthcare institutions in the pilot areas.

China has approximately 100 million COPD patients1. COPD has become the third leading cause of death by disease in China.2 Moreover, the prevalence has significantly increased in recent years,3,4 leading the chronic disease to become as common as hypertension and diabetes. Due to the low awareness and the low diagnosis rate, COPD has posed a huge threat to China's public healthcare system. With the theme of “All Together to End COPD”, this year's World COPD Day calls for all sectors of society to work together to address the major challenges of the disease management. 

Academician Wang Chen, Vice President of the Chinese Academy of Engineering, and President of the Chinese Academy of Medical Sciences and Peking Union Medical College,the treatment of COPD is facing multiple challenges in China, which requires government, healthcare institutions and the public to attach more importance to disease prevention and control, as well as adopt comprehensive approaches to reduce the threat of disease towards public health. 'Xing Fu Hu Xi' project plays a significant role in establishing COPD treatment and management medical consortia, promoting standardised COPD treatment and enhancing disease awareness. The project also provides important reference for improving tiered treatment and long-term management of COPD.

As of the end of October 2019, "Xing Fu Hu Xi" project involved 19 pilot areas for COPD tiered diagnosis and treatment in 18 provinces. More than 1 million people received COPD diagnosis through questionnaire and over 150 thousand people conducted the lung function test, and approximately 7,516 COPD patients have received standardised management. 285 online training programmes and 84 online clinical case discussions have been organised for HCPs, providing trainings of COPD diagnosis and treatment for approximately 360 thousand healthcare professionals.

Huang Zemin, Executive Vice President and Secretary General of the Chinese Association for Health Promotion and Education, made positive comments on the achievements of the project. He pointed out: "The 'Healthy China 2030' plan emphasises the importance and has set goals on improving the awareness and standardised treatment of chronic respiratory disease. With the joint efforts of all the participants, the 'Xing Fu Hu Xi' project phase-II has met all the expected targets. We will further expand the project to improve the COPD disease awareness, as well as promote standardised and long-term management of COPD across various levels of healthcare institutions and contribute to the ‘Healthy China 2030’ vision." 

"Xing Fu Hu Xi" project phase-II has covered 11 pilot areas, including Yinchuan in Ningxia, Datong in Shanxi, Xiangtan in Hunan, Huaihua in Hunan, Hulunbuir in Inner Mongolia, Daqing in Heilongjiang, Tonghua in Jilin, Jinzhou in Liaoning, Heping District of Tianjin, Huangshan in Anhui, and Huzhou in Zhejiang. In 2020, the project will include 10 more pilot areas and will benefit more than 136 million people. 

Dr. James He, Vice President and Head of Medical Affairs of GSK China, said: “We are very glad to see all the accomplishments achieved by 'Xing Fu Hu Xi' project. GSK will continue to work closely with all the partners to provide comprehensive supports for the project, in terms of funding, manpower, technology, data analysis and disease education. We will spare no effort to support the implementation of national policy for tiered diagnosis and treatment of COPD, as well as fulfil our long-term commitment of 'In China, with China, for China' by enabling more patients to breathe with ease."


GSK’s commitment to respiratory disease 

For 50 years, GSK has led the way in developing medicines that advance the management of asthma and COPD. From introducing the world’s first selective short-acting beta agonist in 1969, to launching six treatments in five years to create today’s industry-leading respiratory portfolio, we continue to innovate so we can reach the right patients, with the right treatment. Working together with the healthcare community, we apply world-class science to discover and understand the molecules that become the medicines of tomorrow. We won’t stand still until the simple act of breathing is made easier for everyone. 

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com .


GSK enquiries:

China: Summer Li, summer.n.li@gsk.com



  1. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. The Lancet 2018; 391: 1706-17.
  2. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. The Lancet 2013; 391: 1987-2015.
  3. Zhong N, et al. Am J Respir Crit Care Med. 2007;176(8):753-760.
  4. Wang C. et al. The Lancet 2018; 391 (10131).